国内销售收入短期承压，海外稳步放量。公司25 年上半年实现收入2.78 亿美元，肿瘤业务收入1.44 亿美元，其中肿瘤产品收入0.99 亿美元，同比-29%，主要系呋喹替尼等产品竞争加剧导致国内销售收入下滑；首付款、监管里程碑及研发服务收入为0.44 亿美元，较去年略有增长。公司下调全年肿瘤业务收入指引至2.7-3.5 亿美元，主要系考虑到部分里程碑收入款项延迟确认，以及索乐匹尼布的上市时间推迟。...
Source Link国内销售收入短期承压，海外稳步放量。公司25 年上半年实现收入2.78 亿美元，肿瘤业务收入1.44 亿美元，其中肿瘤产品收入0.99 亿美元，同比-29%，主要系呋喹替尼等产品竞争加剧导致国内销售收入下滑；首付款、监管里程碑及研发服务收入为0.44 亿美元，较去年略有增长。公司下调全年肿瘤业务收入指引至2.7-3.5 亿美元，主要系考虑到部分里程碑收入款项延迟确认，以及索乐匹尼布的上市时间推迟。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.